Orphan Drugs in Treatment of Rare Disease: Advances in Drug Discovery, Regulatory Framework, Clinical Applications and Future Perspectives

Orphan drugs are medicinal products specifically developed for the diagnosis, prevention, or treatment of rare diseases, which collectively affect 300 to 400 million individuals worldwide. Rare diseases are defined by low prevalence, such as less than 200,000 patients in the US or less than 5 out of 10,000 people in the EU. Due to their small patient populations and the high cost of intensive research and development (R&D), these drugs are often commercially unattractive to the pharmaceutical industry. Regulatory Frameworks and Incentives To overcome commercial barriers and address the significant unmet medical need, global regulatory bodies have established incentive- driven frameworks. Key examples include: United States: The Orphan Drug Act (ODA) of1983 provides incentives such as seven years of market exclusivity after approval, tax credits for clinical testing, and fee waivers. European Union: The EU Orphan Regulation (2000) offers ten years of market exclusivity, protocol assistance, and fee waivers. India: The New Drugs & Clinical Trial Regulations (2019) and the 2021 National Policy for Rare Diseases focus on expedited approval (within 90 days), possible local clinical trial waivers, and temporary price control exemptions. Advances in Drug Discovery Recent technological and scientific advancement are transforming the field Genomics and Personalized Medicine: Many rare diseases have a genetic origin (~80%). Advances in genomics enable the development of personalized treatments that provide “the right patient with the right drug at the right dose at the right time” Artificial Intelligence (AI): AI, Machine Learning (ML), and Deep Learning (DL) are vital tools for accelerating diagnosis, target identification, drug repurposing, and optimizing clinical trials. Challenges and Future Directions Despite the successes, several significant challenges persist: High Costs and Affordability: Orphan drugs often carry high prices, sometimes exceeding hundr